Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

In conclusion, inhibition of CIP2A determines the effects of erlotinib on apoptosis in HCC. CIP2A may be useful as a therapeutic biomarker for predicting clinical response to erlotinib in HCC treatment. PMID: 23178652 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/PubMed/23178652?dopt=Abstract

Source: Biochemical Pharmacology - November 23, 2012 Category: Drugs & Pharmacology Authors: Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF Tags: Biochem Pharmacol Source Type: research

More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatocellular Carcinoma | Liver Cancer